Charles A. Deignan
2017
In 2017, Charles A. Deignan earned a total compensation of $847.1K as Chief Financial Officer at Clearside Biomedical, a 32% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $93,259 |
|---|---|
| Option Awards | $459,671 |
| Salary | $289,623 |
| Other | $4,532 |
| Total | $847,085 |
Deignan received $459.7K in option awards, accounting for 54% of the total pay in 2017.
Deignan also received $93.3K in non-equity incentive plan, $289.6K in salary and $4.5K in other compensation.
Rankings
In 2017, Charles A. Deignan's compensation ranked 9,780th out of 14,666 executives tracked by ExecPay. In other words, Deignan earned more than 33.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 9,780 out of 14,666 | 33rd |
Division Manufacturing | 3,780 out of 5,772 | 35th |
Major group Chemicals And Allied Products | 1,312 out of 2,075 | 37th |
Industry group Drugs | 1,059 out of 1,731 | 39th |
Industry Pharmaceutical Preparations | 832 out of 1,333 | 38th |
Source: SEC filing on April 27, 2018.
Deignan's colleagues
We found two more compensation records of executives who worked with Charles A. Deignan at Clearside Biomedical in 2017.
News
Clearside Biomedical CEO George Lasezkay's 2023 pay stays at $1.5M
April 26, 2024
Clearside Biomedical CEO George Lasezkay's 2022 pay falls 35% to $1.5M
April 28, 2023
Clearside Biomedical President and Chief Executive Office George Lasezkay's 2021 pay jumps 71% to $2.3M
April 29, 2022
Clearside Biomedical Chief Commercial Officer Brion Raymond receives $954K in 2018
April 26, 2019